GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lexagene Holdings Inc (OTCPK:LXXGQ) » Definitions » Selling and Marketing Expense

Lexagene Holdings (Lexagene Holdings) Selling and Marketing Expense : $0.39 Mil (TTM As of Nov. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Lexagene Holdings Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Lexagene Holdings's Selling and Marketing Expense for the three months ended in Nov. 2022 was $0.08 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Nov. 2022 was $0.39 Mil.


Lexagene Holdings Selling and Marketing Expense Historical Data

The historical data trend for Lexagene Holdings's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexagene Holdings Selling and Marketing Expense Chart

Lexagene Holdings Annual Data
Trend Mar13 Mar14 Mar15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Selling and Marketing Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 1.32 0.66 0.80 0.93

Lexagene Holdings Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.13 0.09 0.09 0.08

Lexagene Holdings Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Nov. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lexagene Holdings Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of Lexagene Holdings's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexagene Holdings (Lexagene Holdings) Business Description

Traded in Other Exchanges
N/A
Address
500 Cummings Center, Suite 4550, Beverly, MA, USA, 01915
Lexagene Holdings Inc is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

Lexagene Holdings (Lexagene Holdings) Headlines

From GuruFocus

LexaGene Announces Management Cease Trade Order

By PurpleRose PurpleRose 07-10-2022

LexaGene Announces Management Cease Trade Order

By GuruFocusNews GuruFocusNews 06-30-2022

LexaGene Reduces Time-to-Result by ~35%

By PurpleRose PurpleRose 08-10-2022

LexaGene Holdings Proposes to Amend Warrants Terms

By GlobeNewswire GlobeNewswire 10-27-2022

LexaGene Provides MCTO Update

By PurpleRose PurpleRose 07-12-2022

LexaGene Files for Chapter 7 Bankruptcy

By sperokesalga sperokesalga 02-24-2023